S<sup>3.15</sup>,S<sup>3.22</sup>,S<sup>3.29</sup>-[(1,3,5-triazinane-1,3,5-triyl)tris(3-oxopropane-3,1-diyl)]{N-[5-oxo-5-({L-valyl-N<sup>5</sup>-carbamoyl-L-ornithyl[(4-aminophenyl)methoxy]carbonyl-N-methyl-L-valyl-Lvalyl-(3R,4S,5S)-3-methoxy-5-methyl-4-(methylamino)heptanoyl-(2R,3R)-N-[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]-3-methoxy-2-methyl-3-[(2S)-pyrrolidin-2-yl]propanamide}-N2.1-yl)pentanoyl]-?-alanyldecakis(N-methylglycyl)-L-alanyl-N6-carbamimidoyl-L-lysyl-L-?-aspartyl-L-cysteinyl-(4R)-4-hydroxy-L-prolyl-L-leucyl-L-valyl-L-asparaginyl-L-prolyl-L-leucyl-L-cysteinyl-L-leucyl-L-histidyl-L-prolyl-D-?-aspartyl-L-tryptophyl-N6-carbamimidoyl-L-lysyl-Lcysteinamide}
Non-small Cell Lung Cancer
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 59/ 100
Competitive context
1205 Active assets in the Non-small Cell Lung Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Necitumumab Jonsson Comprehensive Cancer Center | Phase 3 | BBB |
Zorifertinib Alpha Biopharma (Jiangsu) Co., Ltd. | Phase 2/3 | BBB |
Glumetinib Shanghai JMT-Bio Inc. | Phase 3 | BBB |
d-0316 Betta Pharmaceuticals Co., Ltd. | Phase 2/3 | BBB |
Onartuzumab Hoffmann-La Roche | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
S<sup>3.15</sup>,S<sup>3.22</sup>,S<sup>3.29</sup>-[(1,3,5-triazinane-1,3,5-triyl)tris(3-oxopropane-3,1-diyl)]{N-[5-oxo-5-({L-valyl-N<sup>5</sup>-carbamoyl-L-ornithyl[(4-aminophenyl)methoxy]carbonyl-N-methyl-L-valyl-Lvalyl-(3R,4S,5S)-3-methoxy-5-methyl-4-(methylamino)heptanoyl-(2R,3R)-N-[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]-3-methoxy-2-methyl-3-[(2S)-pyrrolidin-2-yl]propanamide}-N2.1-yl)pentanoyl]-?-alanyldecakis(N-methylglycyl)-L-alanyl-N6-carbamimidoyl-L-lysyl-L-?-aspartyl-L-cysteinyl-(4R)-4-hydroxy-L-prolyl-L-leucyl-L-valyl-L-asparaginyl-L-prolyl-L-leucyl-L-cysteinyl-L-leucyl-L-histidyl-L-prolyl-D-?-aspartyl-L-tryptophyl-N6-carbamimidoyl-L-lysyl-Lcysteinamide} is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →